Squarepoint Ops LLC increased its position in shares of Cerus Co. (NASDAQ:CERS - Free Report) by 2,084.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 492,732 shares of the biotechnology company's stock after buying an additional 470,178 shares during the period. Squarepoint Ops LLC owned 0.27% of Cerus worth $759,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of CERS. Two Sigma Advisers LP raised its position in shares of Cerus by 249.5% during the fourth quarter. Two Sigma Advisers LP now owns 254,100 shares of the biotechnology company's stock worth $391,000 after purchasing an additional 181,400 shares during the period. Two Sigma Investments LP raised its holdings in Cerus by 121.6% during the fourth quarter. Two Sigma Investments LP now owns 595,234 shares of the biotechnology company's stock worth $917,000 after buying an additional 326,605 shares during the last quarter. State of Wyoming lifted its stake in shares of Cerus by 39.1% in the fourth quarter. State of Wyoming now owns 129,840 shares of the biotechnology company's stock valued at $200,000 after buying an additional 36,488 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Cerus by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 50,817 shares of the biotechnology company's stock valued at $78,000 after buying an additional 16,720 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Cerus by 52.1% during the fourth quarter. Millennium Management LLC now owns 2,877,932 shares of the biotechnology company's stock worth $4,432,000 after acquiring an additional 986,286 shares in the last quarter. Institutional investors own 78.37% of the company's stock.
Insider Activity
In other Cerus news, COO Vivek K. Jayaraman sold 33,999 shares of the business's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $1.50, for a total value of $50,998.50. Following the transaction, the chief operating officer now owns 1,507,315 shares in the company, valued at approximately $2,260,972.50. The trade was a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Mariner Greenman sold 60,984 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $1.50, for a total value of $91,476.00. Following the transaction, the chief executive officer now owns 4,309,758 shares of the company's stock, valued at approximately $6,464,637. This represents a 1.40% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 295,437 shares of company stock worth $435,997. 5.60% of the stock is currently owned by insiders.
Cerus Stock Performance
Shares of Cerus stock traded down $0.04 during trading hours on Thursday, reaching $1.41. The company had a trading volume of 1,175,920 shares, compared to its average volume of 1,282,411. The firm has a market cap of $268.58 million, a PE ratio of -12.86 and a beta of 1.58. Cerus Co. has a one year low of $1.12 and a one year high of $2.54. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The business has a fifty day simple moving average of $1.31 and a 200 day simple moving average of $1.56.
Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The firm had revenue of $43.24 million for the quarter, compared to analysts' expectations of $47.44 million. On average, analysts anticipate that Cerus Co. will post -0.08 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $4.00 target price on shares of Cerus in a report on Friday, February 21st.
Check Out Our Latest Analysis on CERS
Cerus Company Profile
(
Free Report)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
See Also

Before you consider Cerus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.
While Cerus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.